Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2301 to 2310 of 2733 total matches.

In Brief: Defibrotide (Defitelio) for Hepatic Veno-Occlusive Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 12, 2016  (Issue 1503)
properties that protect hepatic endothelial cells from the damage associated with HSCT.1 Approval ...
The FDA has approved defibrotide sodium (Defitelio – Jazz), a mixture of mostly single-stranded polydeoxyribonucleotide sodium salts, for treatment of adults and children with hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome) and renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). It is the first drug to be approved by the FDA for treatment of severe hepatic veno-occlusive disease. Defibrotide was approved earlier by the European Medicines Agency for the same indication.Hepatic veno-occlusive disease is an uncommon (<2%)...
Med Lett Drugs Ther. 2016 Sep 12;58(1503):120 |  Show IntroductionHide Introduction

In Brief: New Benzodiazepine Warnings

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020  (Issue 1610)
and physical dependence.1 Benzodiazepine labels have contained a boxed warning about a risk of serious drug ...
The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine labels have contained a boxed warning about a risk of serious drug interactions with opioids since 2016.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):175 |  Show IntroductionHide Introduction

In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2023  (Issue 1679)
of nonmetastatic castration-resistant prostate cancer (nmCRPC).1 MECHANISM OF ACTION — Androgen receptors ...
The androgen receptor inhibitor darolutamide (Nubeqa – Bayer) has been approved by the FDA for use in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The drug was previously approved for treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC).
Med Lett Drugs Ther. 2023 Jun 19;65(1679):e108   doi:10.58347/tml.2023.1679h |  Show IntroductionHide Introduction

In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
duration of response was 14 months.1 ADVERSE EFFECTS — In the FOCUS trial, cytopenias, fatigue, nausea ...
...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e148   doi:10.58347/tml.2023.1684d |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
in the US; it is about 2.5 times more common in women than in men.1 Guidelines for treatment of RA from the American ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
(AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 ...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 |  Show IntroductionHide Introduction

Choice of Benzodiazepines

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 1988  (Issue 760)
-qid 4.24 Valium (Roche) 12.38 Q-Pam (Quantum) 1.13 Lorazepam - average generic price intermediate ...
Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the benzodiazepines available for oral use in the USA are listed in the table on page 28.
Med Lett Drugs Ther. 1988 Feb 26;30(760):26-8 |  Show IntroductionHide Introduction

Cefuroxime Axetil

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 1988  (Issue 767)
elimination half-life is 1.2 hours. The major route of excretion is renal, by both glomerular The Medical ...
Cefuroxime axetil (Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime (Zinacef), was recently marketed in the USA. Previously available oral cephalosporins are the first-generation drugs cephalexin (Keflex; and others), cephradine (Anspor; and others) and cefadroxil (Duricef; and others), and the second-generation cefaclor (Ceclor); second-generation cephalosporins have more activity against gram-negative bacteria.
Med Lett Drugs Ther. 1988 Jun 3;30(767):57-9 |  Show IntroductionHide Introduction

Cefixime - A New Oral Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Aug 11, 1989  (Issue 798)
for patients with renal impairment. COST OF SOME ANTIMICROBIALS Pediatric Adult Drug Dosage 1 Cost 2 ...
Cefixime (Suprax - Lederle), an oral cephalosporin antibiotic, was recently approved for marketing by the US Food and Drug Administration. Claimed to be the first oral third-generation cephalosporin, the new drug is offered for once-a-day treatment of otitis media, pharyngitis, bronchitis and urinary tract infections.
Med Lett Drugs Ther. 1989 Aug 11;31(798):73-5 |  Show IntroductionHide Introduction

Fluconazole

   
The Medical Letter on Drugs and Therapeutics • May 18, 1990  (Issue 818)
Saag and WE Dismukes, Antimicrob Agents Chemother, 32:1, 1988). PHARMACOKINETICS — In comparison ...
Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.
Med Lett Drugs Ther. 1990 May 18;32(818):50-2 |  Show IntroductionHide Introduction